Literature DB >> 24777312

C5a2 can modulate ERK1/2 signaling in macrophages via heteromer formation with C5a1 and β-arrestin recruitment.

Daniel E Croker1, Reena Halai1, Geraldine Kaeslin1, Elisabeth Wende2, Beate Fehlhaber2, Andreas Klos2, Peter N Monk3, Matthew A Cooper1.   

Abstract

The complement system is a major component of our innate immune system, in which the complement proteins C5a and C5a-des Arg bind to two G-protein-coupled receptors: namely, the C5a receptor (C5a1) and C5a receptor like-2 receptor (C5a2, formerly called C5L2). Recently, it has been demonstrated that C5a, but not C5a-des Arg, upregulates heteromer formation between C5a1 and C5a2, leading to an increase in IL-10 release from human monocyte-derived macrophages (HMDMs). A bioluminescence resonance energy transfer (BRET) assay was used to assess the recruitment of β-arrestins by C5a and C5a-des Arg at the C5a1 and C5a2 receptors. C5a demonstrated elevated β-arrestin 2 recruitment levels in comparison with C5a-des Arg, whereas no significant difference was observed at C5a2. A constitutive complex that formed between β-arrestin 2 and C5a2 accounted for half of the BRET signal observed. Interestingly, both C5a and C5a-des Arg exhibited higher potency for β-arrestin 2 recruitment via C5a2, indicating preference for C5a2 over C5a1. When C5a was tested in a functional ERK1/2 assay in HMDMs, inhibition of ERK1/2 was observed only at concentrations at or above the EC50 for heteromer formation. This suggested that increased recruitment of the β-arrestin-C5a2 complex at these C5a concentrations might have an inhibitory role on C5a1 signaling through ERK1/2. An improved understanding of C5a2 modulation of signaling in acute inflammation could be of benefit in the development of ligands for conditions such as sepsis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24777312     DOI: 10.1038/icb.2014.32

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  20 in total

1.  Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.

Authors:  Daniel E Croker; Peter N Monk; Reena Halai; Geraldine Kaeslin; Zoe Schofield; Mike Cl Wu; Richard J Clark; Mark At Blaskovich; Dimitrios Morikis; Christodoulos A Floudas; Matthew A Cooper; Trent M Woodruff
Journal:  Immunol Cell Biol       Date:  2016-04-25       Impact factor: 5.126

2.  The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages.

Authors:  Songlin Yu; Dan Wang; Lingmin Huang; Yening Zhang; Ruiheng Luo; Dickson Adah; Yiting Tang; Kai Zhao; Ben Lu
Journal:  J Biol Chem       Date:  2019-04-10       Impact factor: 5.157

3.  T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival.

Authors:  Divya A Verghese; Markus Demir; Nicholas Chun; Miguel Fribourg; Paolo Cravedi; Ines Llaudo; Trent M Woodruff; Pragya Yadav; Sergio A Lira; M Edward Medof; Peter S Heeger
Journal:  J Immunol       Date:  2018-02-07       Impact factor: 5.422

4.  Differential capacity for complement receptor-mediated immune evasion by Porphyromonas gingivalis depending on the type of innate leukocyte.

Authors:  G Hajishengallis; J L Krauss; R Jotwani; J D Lambris
Journal:  Mol Oral Microbiol       Date:  2016-05-18       Impact factor: 3.563

Review 5.  Complement and the Regulation of T Cell Responses.

Authors:  Erin E West; Martin Kolev; Claudia Kemper
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 28.527

Review 6.  More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation.

Authors:  George Hajishengallis; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

7.  Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays In Vitro and In Vivo.

Authors:  Declan M Gorman; Xaria X Li; Colton D Payne; Cedric S Cui; John D Lee; K Johan Rosengren; Trent M Woodruff; Richard J Clark
Journal:  ACS Pharmacol Transl Sci       Date:  2021-11-17

8.  Folic acid-mediated fibrosis is driven by C5a receptor 1-mediated activation of kidney myeloid cells.

Authors:  Ranjit K Sahu; Sandhya Xavier; Daniel Chauss; Luopin Wang; Claude Chew; Ronald Taylor; William B Stallcup; Jennie Z Ma; Majid Kazemian; Behdad Afzali; Jörg Köhl; Didier Portilla
Journal:  Am J Physiol Renal Physiol       Date:  2022-04-04

9.  C3 Drives Inflammatory Skin Carcinogenesis Independently of C5.

Authors:  William D Jackson; Alessandro Gulino; Liliane Fossati-Jimack; Rocio Castro Seoane; Kunyuan Tian; Katie Best; Jörg Köhl; Beatrice Belmonte; Jessica Strid; Marina Botto
Journal:  J Invest Dermatol       Date:  2020-07-16       Impact factor: 8.551

10.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Authors:  Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.